Senti Biosciences director Edward Mathers resigns from board

Senti Biosciences Holdings, Inc. disclosed in an 8-K filing that Edward Mathers notified the Board of Directors of his decision to resign from the Board, effective immediately, on October 27, 2026¹. The filing also states that Mathers resigned from all committees of the Board on which he served, effective immediately, in connection with his board departure¹. The company said it thanks him for his service, according to the filing.

In a separate matter disclosed in the same 8-K, Senti's board took action related to a previously announced corporate transaction. The filing states that on October 26, 2026, the Board of Directors fixed the close of business on October 30, 2026 as the record date for the company's previously announced distribution of contingent value rights, in connection with the closing on October 21, 2026 of transactions contemplated by an Agreement and Plan of Merger dated July 14, 2026, among the Company, Senti Holdings, Inc. (described as a wholly owned subsidiary of the Company and referred to as "Midco"), Senti Biosciences, Inc. (a Delaware corporation and wholly owned subsidiary of Midco), ST NewCo Limited (formerly known as Celadon Partners SPV 35 Limited), and Senti Merger Sub, Inc.¹

The filing was signed by Timothy Lu, M.D., Ph.D., identified as Chief Executive Officer, and dated October 27, 2026, according to the document's signature page.